Angiopoietin-Like Protein 3 (ANGPTL3) Modulates Lipoprotein Metabolism and Dyslipidemia

doi:10.3390/ijms22147310

Chia Nan University of Pharmacy & Science Institutional Repository > 藥理學院 > 生物科技系(所) > 期刊論文 > Item 310902800/34397

請使用永久網址來引用或連結此文件: https://ir.cnu.edu.tw/handle/310902800/34397

標題:	Angiopoietin-Like Protein 3 (ANGPTL3) Modulates Lipoprotein Metabolism and Dyslipidemia
作者:	Chen, Pei-Yi Gao, Wan-Yun Liou, Je-Wen Lin, Ching-Yen Wu, Ming-Jiuan Yen, Jui-Hung
貢獻者:	Buddhist Tzu Chi Med Fdn, Hualien Tzu Chi Hosp, Ctr Med Genet Tzu Chi Univ, Dept Mol Biol & Human Genet Tzu Chi Univ, Inst Med Sci Tzu Chi Univ, Sch Med, Dept Biochem Chia Nan Univ Pharm & Sci, Dept Biotechnol
關鍵字:	dyslipidemia TG-rich lipoproteins ASCVDs ANGPTL3 lipoprotein lipase
日期:	2021
上傳時間:	2023-11-11 11:49:34 (UTC+8)
出版者:	MDPI
摘要:	Dyslipidemia is characterized by increasing plasma levels of low-density lipoprotein-cholesterol (LDL-C), triglycerides (TGs) and TG-rich lipoproteins (TGRLs) and is a major risk factor for the development of atherosclerotic cardiovascular disorders (ASCVDs). It is important to understand the metabolic mechanisms underlying dyslipidemia to develop effective strategies against ASCVDs. Angiopoietin-like 3 (ANGPTL3), a member of the angiopoietin-like protein family exclusively synthesized in the liver, has been demonstrated to be a critical regulator of lipoprotein metabolism to inhibit lipoprotein lipase (LPL) activity. Genetic, biochemical, and clinical studies in animals and humans have shown that loss of function, inactivation, or downregulated expression of ANGPTL3 is associated with an obvious reduction in plasma levels of TGs, LDL-C, and high-density lipoprotein-cholesterol (HDL-C), atherosclerotic lesions, and the risk of cardiovascular events. Therefore, ANGPTL3 is considered an alternative target for lipid-lowering therapy. Emerging studies have focused on ANGPTL3 inhibition via antisense oligonucleotides (ASOs) and monoclonal antibody-based therapies, which have been carried out in mouse or monkey models and in human clinical studies for the management of dyslipidemia and ASCVDs. This review will summarize the current literature on the important role of ANGPTL3 in controlling lipoprotein metabolism and dyslipidemia, with an emphasis on anti-ANGPTL3 therapies as a potential strategy for the treatment of dyslipidemia and ASCVDs.
關聯:	INT J MOL SCI, v.22, n.14
顯示於類別:	[生物科技系(所)] 期刊論文

文件中的檔案:

檔案	描述	大小	格式	瀏覽次數
ijms-22-07310.pdf		1590Kb	Adobe PDF	102	檢視/開啟
index.html		0Kb	HTML	277	檢視/開啟

在CNU IR中所有的資料項目都受到原著作權保護.

TAIR相關文章

資料載入中.....